Andera Partners

Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.

Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Resonance Imaging Group operates medical imaging centers in Franconville, France, focusing on providing access to various imaging services for accurate diagnoses. The company specializes in several areas, including neuroimaging, oncology imaging, chest imaging, thyroid imaging, urinary imaging, virtual colonoscopy, and visceral imaging. Through its network of centers and advanced imaging technology, Resonance Imaging aims to enhance diagnostic precision and improve patient outcomes.

HR Path is a global consultancy specializing in human capital management, with a focus on HR Systems Integration, HR Outsourcing, and HR Business Consulting. Founded in 2001 by François Boulet and Cyril Courtin, the company is headquartered in Paris and operates in 13 countries across North America, Europe, and the Middle East, employing over 500 consultants. HR Path offers a range of software solutions, including proprietary tools like BiHRdy for business intelligence, Pandore for HR and payroll management, and Geef for talent management. Additionally, it serves as an authorized reseller for various software solutions in the French market, including those from SAP and Oracle HCM. With a diverse client portfolio that includes large corporations, small and medium-sized enterprises, and public sector organizations, HR Path generates approximately €60 million in annual revenue, supporting clients in their digital transformation and enhancing the efficiency of HR operations through technology.

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients.

Kyotherm SAS is an investment company based in Paris, France, that focuses on financing renewable heating and energy efficiency projects. Established in 2011, it provides project equity to support the development of energy infrastructure and acquires stakes in various renewable energy production initiatives, including geothermal and biomass heating plants, as well as district heating networks. Kyotherm collaborates with a range of stakeholders, including energy service providers, engineering firms, developers, heat consumers, and equipment manufacturers, to facilitate third-party financing for these projects.

TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

Lhyfe is a company based in Nantes, France, that specializes in the design, development, and operation of industrial sites for the production of green hydrogen sourced from renewable energy. Established in 2017, Lhyfe focuses on supplying 100% green hydrogen to support mobility and industrial applications. The company's commitment to sustainable energy solutions positions it as a key player in the transition towards greener energy sources.

Provider of real estate investment and management services intended for both individuals and institutions or private companies. The company's services include asset management, compelling investment opportunities, investment discipline, alignment of interests, strategic and institutional risk management compliance, enabling clients to access proper mediums for their investment and expansion.

exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using such compositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses.

Evommune, Inc. is a biotechnology company based in Los Altos, California, focused on developing and manufacturing tissue-based medicines for inflammatory diseases. Established in 2020, the company aims to improve the quality of life for patients by addressing the underlying causes of these conditions. Evommune employs a proprietary tissue-based platform designed to accelerate the discovery of novel therapies while predicting their clinical success. This innovative approach enhances the capabilities of health professionals in the fields of immunology and dermatology, allowing for the development of treatments that effectively target symptoms and hinder disease progression.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

MC2-Technologies develops innovative equipment for the protection of sites or sensitive infrastructures.

Manufacturer of vehicle-mounted access platforms. The company engages in the manufacturing of vehicle-mounted elevators and platforms for various types of commercial vehicles and trucks, enabling users to seamlessly carry out their tasks.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products. The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials. It was established in Galway, Galway in 2013.

Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.

Sogetrel, S.A.S. specializes in designing, deploying, and maintaining network infrastructures and digital communication solutions. The company integrates communication systems and offers services for telecommunications networks, including deployment, connection, and commissioning. Additionally, Sogetrel provides IP security solutions, such as video surveillance systems, access control, and intrusion detection, along with consulting for smart city projects. The company serves a diverse range of sectors including telecommunications, public authorities, transportation, defense, and utilities. Founded in 1985 and headquartered in Issy les Moulineaux, France, Sogetrel has expanded its presence with branches in Belgium and Switzerland, positioning itself as a key player in the telecom market and a trusted partner for major operators and contractors.

SIRSA develops Reporting 21, a Software as a Service platform for the collection and analysis of financial and extra-financial data. It serves businesses and financial institutions. The company was incorporated in 2014 and is based in Paris, France.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Opportunity SAS is a company based in Paris, France, founded in 2005, specializing in debt recovery and risk management solutions. It provides a comprehensive range of services including payment reminders, card protection, survey design, personal video communications, video signatures, record signatures, push notifications, and mail services. Additionally, Opportunity offers multi-channel delivery capabilities, data integration, and portal services. The company also focuses on marketing automation and provides a software as a service (SaaS) platform for customer interaction management. Opportunity is recognized for its commitment to enhancing digital customer relationship management projects, serving clients across various sectors both in France and internationally.

MasterGrid is a manufacturer and supplier of high voltage electrical equipment based in Grenoble, France. Formerly known as Merlin Gerin, the company was incorporated in 2019 and focuses on providing electric products, solutions, and services tailored to the needs of both the commercial and industrial sectors.

Olaqin SAS is a French company based in Suresnes that specializes in electronic healthcare transaction management systems. Founded in 2012, it provides a range of solutions including self-service and counter payment terminals, mobile payment options, and health management software. Olaqin serves pharmacies, healthcare professionals, and medical institutions by facilitating efficient transactions and enhancing the management of electronic care records. The company's offerings include centralized payment services, securing electronic care sheets, updating vitale cards, and providing secure access to online medical records. Olaqin aims to improve transaction processes within the healthcare sector, thereby supporting the needs of its clients.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Ellisphere is a business intelligence platform that specializes in providing decision-making information to executives and decision-makers in France and internationally. Through its BIGnet network, it offers economic and financial insights on trading partners, facilitating informed decision-making. The platform delivers a comprehensive view of customer and supplier portfolios while also offering guidance on legislation and regulatory compliance. Additionally, it supports businesses in developing customer base strategies, ultimately promoting sustainable growth and development.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

99 Advisory is a banking and insurance sectors are facing radical changes in their environments.

Travelsoft SAS, founded in 2016 and based in Paris, France, develops software solutions specifically tailored for the travel industry. The company offers Orchestra, a Software-as-a-Service platform designed to assist professionals in producing, administrating, distributing, and managing leisure services within the travel sector. Through its innovative software offerings, Travelsoft aims to enhance operational efficiency and streamline processes for various stakeholders in the travel market.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Spherea Test & Services SAS is a manufacturer specializing in the development, production, and maintenance of test equipment for various sectors, including aviation, defense, space, energy, railways, and transportation. The company offers a range of products such as automatic test equipment, final assembly line test tools, wiring testers, and optical instruments for small equipment. Additionally, Spherea provides military support solutions, instrumentation and control systems, and a variety of services including sustainability, total maintenance, and printed circuit board cloning. Founded in 1999 and headquartered in Toulouse, France, Spherea has expanded its presence globally with offices in the United States, Singapore, and China, as well as design and production facilities in France, Germany, and the United Kingdom. The company was previously known as Cassidian Test & Services SAS before rebranding in 2010.

HR Path is a global consultancy specializing in human capital management, with a focus on HR Systems Integration, HR Outsourcing, and HR Business Consulting. Founded in 2001 by François Boulet and Cyril Courtin, the company is headquartered in Paris and operates in 13 countries across North America, Europe, and the Middle East, employing over 500 consultants. HR Path offers a range of software solutions, including proprietary tools like BiHRdy for business intelligence, Pandore for HR and payroll management, and Geef for talent management. Additionally, it serves as an authorized reseller for various software solutions in the French market, including those from SAP and Oracle HCM. With a diverse client portfolio that includes large corporations, small and medium-sized enterprises, and public sector organizations, HR Path generates approximately €60 million in annual revenue, supporting clients in their digital transformation and enhancing the efficiency of HR operations through technology.

Tournus Equipement, S.A.S. is a manufacturer based in Tournus, France, specializing in stainless steel environments for professional kitchens and supermarket fish counters. The company provides a wide range of products, including mobile, modular, and customizable professional kitchens, regeneration ovens, warmers, sterilizing cabinets, and various types of washbasins and dishwashing equipment. Additionally, Tournus Equipement offers shelving products, bins, and tables for loading and unloading dishwashers, as well as self-service lines for meal distribution. Their clientele encompasses diverse sectors such as restaurants, canteens, bakeries, and supermarkets. Founded in 1910, the company also offers services like joint design, installation, and express delivery to enhance customer experience.

Verbraeken Infra NV specializes in the construction and renovation of underground and overhead utility infrastructure across Europe and North Africa. Established in 1966 and headquartered in Temse, Belgium, the company provides a wide range of services including earth and roadworks, installation of pipelines, sewers, water mains, and district heating systems. Additionally, Verbraeken Infra offers electrical services such as the installation of underground transmission cables, medium- and low-voltage cables, and the maintenance of public lighting. The company also engages in the installation of traditional copper and coaxial cables and employs advanced techniques like horizontal directional drilling and pipe jacking. With an annual revenue of approximately €140 million and a workforce of around 1,000 employees, Verbraeken Infra has expanded its operations in Belgium, France, and Germany, bolstering its market presence through both organic growth and strategic acquisitions.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.

Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products. The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials. It was established in Galway, Galway in 2013.

Lease Protect France SAS is a company based in Marseille, France, established in 2009, that specializes in the installation, servicing, and maintenance of video surveillance and security systems. Its offerings include anti-theft gates, closed-circuit televisions, fog generators, and electronic plotters. The company focuses on combating shrinkage, particularly for small and medium-sized businesses, by providing tailored solutions that leverage the latest connected technologies. With additional offices located across France, Lease Protect emphasizes local proximity and responsive service, complemented by innovative financing options for its products and services.

exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using such compositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses.

Bioclinic operates a network of medical analysis laboratories in the Ile-de-France region, serving health professionals, hospitals, clinics, care centers, and retirement homes. Founded in 1995 and based in Paris, the company specializes in areas such as molecular biology, genetics, antibiotic resistance, and reproductive health. By focusing on these fields, Bioclinic aims to provide clients and their patients with enhanced medical diagnostic results.

Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products. The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials. It was established in Galway, Galway in 2013.

Solware Group operates as a software publisher for actors in the medico-social sector. Solware Group offer innovative, robust and scalable software that responds appropriately to the needs of users and the challenges of their business dailies.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Groupe JORYF is specialist group of housing construction in Ile-de-France.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Skill and You is the leading provider of vocational e-learning in France with its commitments to innovation and professionalism. Employment is a major issue today, and Skill and You is positioned to deliver to learners real results and qualifications (BAC PRO, BEP, BP, BTS, CAP) via our effective pedagogy and adaptable education technology. Leveraging our group’s experiences and deep knowledge, we’ve built a strong track record of successful schools across sectors, empowering learners to change their lives.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Orbility is a developer of off-street parking applications and programs aimed at enhancing transportation systems. The company provides a range of solutions, including automated fare-collection systems, real-time passenger information systems, and vehicle tracking and management tools. These offerings enable clients, which include airports, shopping centers, municipalities, and both public and private operators, to gain complete operational and management control over their parking systems. By focusing on improving the efficiency and effectiveness of public transport systems, Orbility aims to streamline parking operations and enhance overall user experience.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.

TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

BIOGROUP-LCD, a major French player in local medical biology, supports more than 20,000 patients every day and offers more than 2000 routine and specialized daily examinations, based on performance and technological innovation. Partner at every moment between the patient and the medical profession, your laboratory participates in the screening, diagnosis, monitoring and prognosis of the most common pathologies to the most demanding, throughout your course of care. BIOGROUP-LCD develops for this purpose all its human and technological resources. The team of qualified, qualified medical biologists follows continuous and regular training.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Walor SPF SAS, founded in 1994 and based in Saint-Pierre-en-Faucigny, France, operates as a subsidiary of ACI Groupe. The company is a leading European manufacturer of high-precision mechanical parts, specializing in the design, production, and assembly of components primarily for the automotive and energy sectors. With 12 production sites across five countries and a workforce of approximately 1,600 employees, Walor focuses on cold forging, machining, and heat treatment processes to create forgings and machined parts, including those for engines, gearboxes, and steering systems. Its clientele includes major manufacturers, system operators, and automotive suppliers, reflecting its commitment to meeting market and technical requirements for quality, cost, and capacity in automotive mechanical components.

TimeOne, established in 2016, is a marketing services group formed by the merger of two online marketing specialists, Public-Idées and Place des Leads. The company specializes in providing content and data solutions, focusing on prescriptive marketing strategies supported by a robust technological foundation. TimeOne offers a diverse array of online marketing services, including programmatic advertising, native advertising, performance marketing, digital marketplaces, publishing, and mobile solutions. The firm is dedicated to all stages of the client conversion funnel, facilitating branding, engagement, conversion, and re-purchasing through its various online marketing channels. With a strong presence in France, the United Kingdom, Spain, Italy, South Africa, Asia, and South America, TimeOne has established a reputation for innovation driven by research and development in the marketing sector.

GLOBE Groupe sa provides advertising services. The company offers strategic planning and communication strategy services. It also provides advertising, non-media planning, talent castings, recruitment, training, and payroll services. The company also offers storage, kitting, dispatch, cold-chain logistics, stand installation, after-sales checks, parking reservations, and permits. It caters to consumer goods, media, retailers, media, and recruitment industries. GLOBE Groupe sa is based in Paris, France.

La Vie Saine is a retailer based in Montgolfier, France, specializing in organic products since its founding in 1952. The company offers a diverse range of items, including dairy products, fruits and vegetables, specialized foods such as eggs and poultry, grocery items, bakery products, hygiene products, and wine. In addition to food, La Vie Saine provides certified ecological cosmetic products for babies and children, as well as organic cosmetics, grains, cereals, and food supplements. The company is committed to ensuring quality by sourcing products made from natural ingredients. Its headquarters are located in Dijon, France.

Loyalty Company is a marketing consulting firm that specializes in customer communication and advisory services. The company focuses on harnessing the power of data and technology to enhance business performance. Its offerings include customer marketing, sales promotion, and branding services, which are designed to integrate data analysis, creative strategies, and technological insights. Through this approach, Loyalty Company aims to help clients establish strong, customer-centric brands and foster profitable, long-term relationships with their customers.

Allodiagnostic SAS, established in 2001 and headquartered in Paris, France, specializes in providing real estate diagnostics for private individuals during property rentals or sales. The company offers a range of assessments, including termite inspections, electrical evaluations, and energy performance analyses, ensuring compliance with mandatory regulations. As a dedicated service provider for both individuals and real estate professionals, Allodiagnostic tailors its solutions to meet specific client needs. Since July 2017, the company has operated as a subsidiary of Edmond de Rothschild (France), enhancing its capabilities in the real estate diagnostic sector.

IN’TECH MEDICAL is an industry leader in the development and manufacturing of surgical instruments for the Orthopaedic industry. IN’TECH delivers expertise in all aspects of surgical instrument including development and manufacturing. Their services encompass contract manufacturing and contract designing. IN’TECH have a strong track record of turning original ideas into new solutions for their customers.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing innovative treatments for severe diseases involving fibrosis and inflammation. Founded in 2008, Complexa specializes in the research and development of endogenous human cell signaling technologies, particularly through the synthesis of endogenous nitro-fatty acids. Their lead compound, CXA-10, is an oral nitrated fatty acid being developed for the treatment of focal segmental glomerulosclerosis and pulmonary arterial hypertension. The company aims to enhance existing anti-inflammatory and metabolic signaling pathways to promote recovery from acute and chronic tissue injuries and diseases, targeting a range of inflammatory, fibrotic, and central nervous system disorders.

Sarawak Group is a company specialized in setting up Sales-, Merchandising- and Brand Activation services. We seek to accelerate the performance and results of sales of products and services of our customers.

Studia S.A.S. is a consultancy firm based in Meyreuil, France, specializing in enterprise content management (ECM) and document engineering. Founded in 2009, the company provides a range of services, including strategic consulting, implementation advice, digital data processing support, and risk control. Studia also focuses on digital transition and business support, helping clients manage their documentary heritage and sensitive data. Its clientele includes sectors such as energy, industry, rail transport, aeronautics, and defense, where it assists in the production, flow management, digitization, dissemination, and archiving of various types of documents. By enabling clients to enhance their media and content management capabilities, Studia plays a crucial role in navigating complex environments.

Groupe 3S SAS, established in 2001 and based in Roissy-en-France, France, specializes in ground handling services for airlines and support for airport managers. The company offers a comprehensive suite of services that includes passenger and baggage handling, load control, ramp activity, and crew management. Additionally, it provides airport services such as assistance for individuals with disabilities, taxi area management, baggage trolley services, aircraft de-icing, and overall airport cleanliness. Beyond airport-related services, Groupe 3S also engages in industrial cleaning, facility management, and home support services. The company is recognized for its training programs in aviation security, handling of dangerous goods, and ground operations. Through the expertise of its subsidiaries, Groupe 3S has positioned itself as a leader in the global services market for aviation and airport management.

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.

Klaxcar France S.A., founded in 1993 and headquartered in Dourdan, France, specializes in the design and manufacture of automotive spare parts for the aftermarket sector. The company provides Original Part quality products at competitive prices, offering a diverse range of components including lamps, wiper blades, glow and spark plugs, horns, belts, water pumps, and brake discs. By supplying a comprehensive selection of spare parts from a single source, Klaxcar aims to meet the needs of the automobile sector effectively.

Minafin is a global developer and manufacturer of fine chemicals, focusing on active ingredients, organic intermediates, and specialty chemicals tailored for the life sciences and technical applications. The company serves various sectors, including personal care, agriculture, and high-value industrial markets. Minafin offers a diverse portfolio of services and products, which includes building blocks, generic and patented active ingredients, and synthesis intermediates. Through its expertise in fine chemicals, Minafin aims to provide innovative solutions to meet the demands of its clients in these industries.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Bacacier is a manufacture steel and the associated CO2 emissions have been halved.

Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Groupe NetCo specializes in the design, manufacture, assembly, maintenance, and installation of conveyor systems, including both belt and roller types. The company offers a diverse range of conveyor belts made from rubber and various polymers, along with specialized accessories such as wipers, rollers, and drive pulleys. NetCo also provides services like on-site installation, training for conveyor belt operation, and custom transformations of conveyor belts. Serving a wide array of industries, including waste management, logistics, agrifood, pharmaceuticals, and energy sectors, the company has established itself as a leader in the domestic market within a decade of operation. Founded in 1902 and based in Bordeaux, France, Groupe NetCo was previously known as PERRIEZ and rebranded in 1999.

Specialist manufacturer and private labeller of chemicals and solvents. Retail / Wholesale packaging and distribution services.

The Reefer Group SL, based in Alzira, Spain, designs and manufactures refrigerated semi-trailers and vehicles for temperature-controlled transportation both in France and internationally. The company provides a range of new and used semi-trailers, trucks, tractor-trailers, removable bodies, and utility vehicles, catering to the transport of meat, dairy products, fruits, vegetables, flowers, and pharmaceuticals. In addition to manufacturing, The Reefer Group offers spare parts, servicing and repairs, and rebuilding services. Their service portfolio includes liveries, rentals, after-sales training, vehicle upgrades, and the sale of second-hand vehicles. The company's products are distributed through an extensive sales network, supporting a diverse array of refrigerated transport needs. Established in 2015, The Reefer Group has positioned itself as a key player in the refrigerated transportation sector.

MS Vacances SAS, established in 1992 and located in Nantes, France, specializes in hospitality and lodging services. The company operates holiday homes across France, providing a range of amenities including camping facilities, indoor pools, bars, restaurants, grocery stores, and laundry services. Additionally, MS Vacances offers premium air travel options for destinations in the Atlantic and Mediterranean regions, enhancing its service portfolio in the leisure and tourism sector.

Mondial Pet Distribution S.p.A. is an Italian company based in Fossano that specializes in the distribution of hygiene and personal care products for animals, marketed under the Fortesan brand. Established as a subsidiary of Agrifarma S.p.A. since April 2018, the company focuses on providing high-quality products to ensure the well-being of pets.

Fortesan cares about your animals and takes care of them.

The IPSIDE firm assists and advises clients in the process of obtaining, operation and defense of their patents of invention, both in France and abroad. Other ways to protect technical inventions are also included to allow the implementation of the overall strategy of the most appropriate Intellectual Property for the company. We also assist our clients in the development of their technical and legal strategies for operation of their inventions.

Orchestra is an online platform dedicated to the travel industry. It enables professionals to produce, administrate, distribute, and manage leisure offers on many distribution channels. Orchestra is based in Lopera, Spain.

Atland is a global real estate firm founded in 2006, specializing in both housing and commercial real estate markets. The company operates primarily in the Ile-de-France region and other areas, focusing on investment, asset management, and the execution of turnkey developments. Atland also manages collective real estate funds through its subsidiary, Voisin. Its clientele includes individuals, corporations, and institutional investors, reflecting a diverse approach to the real estate sector. The firm is supported by notable shareholders, including Crédit Foncier, Tikéhau Capital, and Edmond de Rothschild Investment Partners.

Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.

Allecra Therapeutics GmbH, founded in 2013 and based in Weil am Rhein, Germany, focuses on developing innovative pharmaceuticals to address gram-negative multi-drug-resistant bacterial infections. The company is currently advancing a novel β-lactamase inhibitor through Phase 2 clinical development. This new treatment aims to counteract the resistance mechanisms of difficult-to-treat bacteria, which are particularly prevalent in hospital-acquired infections. By inhibiting β-lactamases, Allecra's approach directly targets the challenges posed by these resistant strains, providing healthcare providers with effective options to manage infections that may otherwise be inadequately treated. Situated in the BioValley Life Sciences region, Allecra Therapeutics is committed to delivering solutions that can save lives and improve patient outcomes in the face of rising antibiotic resistance.

MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.

La Toulousaine is a French company based in Escalquens, established in 1975, that specializes in the design and manufacture of various building materials. The company produces an extensive range of products, including gates, fences, garage doors, sectional doors, shutters, and security railings. Additionally, La Toulousaine offers metal curtains and mechanical shutters tailored for commercial establishments. Its product line also includes automatic systems and accessories to enhance functionality and security. With a focus on both residential and industrial applications, La Toulousaine serves a diverse clientele in the building materials sector.

Sogetrel, S.A.S. specializes in designing, deploying, and maintaining network infrastructures and digital communication solutions. The company integrates communication systems and offers services for telecommunications networks, including deployment, connection, and commissioning. Additionally, Sogetrel provides IP security solutions, such as video surveillance systems, access control, and intrusion detection, along with consulting for smart city projects. The company serves a diverse range of sectors including telecommunications, public authorities, transportation, defense, and utilities. Founded in 1985 and headquartered in Issy les Moulineaux, France, Sogetrel has expanded its presence with branches in Belgium and Switzerland, positioning itself as a key player in the telecom market and a trusted partner for major operators and contractors.

Fondée en 1999, SFAM est une société de courtage en assurances, filiale de SFK Group. Dotée d’un capital de 2 000 000 d’euros, SFAM crée, commercialise et gère des solutions et des services d'assurance affinitaires. A ses débuts, SFAM se spécialise dans la conception de produits d'assurance destinés exclusivement aux domaines du multimédia et de la téléphonie. Puis elle élargit petit à petit son offre au domaine de l'optique, de l'électroménager, de l'e-commerce, de la protection conducteur et plus récemment à l’ensemble des produits connectés du foyer. Toujours attentive à l'évolution des besoins de ses clients et du marché, la société intègre au fil des années de nouveaux domaines d'activité et accroît par la même occasion sa notoriété. Soucieuse d'innover et de développer les services attendus par ses clients, SFAM propose dès 2009, dans le cadre de ses solutions d'assurances mobile et multimédia, la prise en compte de la perte de l’appareil assuré et de la négligence dans la réalisation des sinistres. En 2013, elle innove de nouveau en intégrant aux contrats d’assurance la reprise des anciens téléphones portables. La flexibilité des garanties et l'éventail des formules proposées par SFAM sont très certainement au cœur de sa réussite. En recherche constante d’équilibre entre ses offres commerciales, leur rapport qualité-prix et la qualité des garanties proposées, SFAM se positionne rapidement comme un acteur majeur de son secteur d'activité. Elle compte actuellement plus de 500 000 clients et de 1500 partenaires installés sur l’ensemble du territoire. Dans sa relation avec ses partenaires commerciaux, SFAM met un point d’honneur à leur délivrer la meilleure formation et à les accompagner dans l’amélioration de leur service clientèle. Elle met ainsi ses 110 collaborateurs à leur disposition afin de leur offrir leur expertise et leur savoir-faire dans les différents domaines d'activité. Egalement très proche de ses adhérents, la société SFAM accorde également une place essentielle à son service clientèle. Elle met en effet à leur disposition un système de traitement des demandes et de gestion des réponses permettant de satisfaire aux mieux ses clients. Par le biais d'un service client multicanal, la SFAM offre une écoute et une disponibilité très large à l'ensemble de ses interlocuteurs. SFAM ne cesse de poursuivre son ascension dans le monde des assurances ; le secret de son succès étant sans nul doute la combinaison de son esprit novateur et de sa proximité avec ses clients.

Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

GamaMabs Pharma SA engages in the development of a new therapeutic antibody for the treatment of ovarian cancer. The company was founded in 2013 and is based in Toulouse, France.

REALEASE Capital offers leasing and financing solutions to the manufacturers of material of videoconference. The company was formerly known as Comiris Capital. The company was founded in 1986 and is based in Puteaux, France.